This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. AR-711 (COVID-19). AR-201 (RSV infection).
Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Patients with severe COVID-19 infection often present with acute severe inflammation and organ failure.
doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.
The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”).
million and US$1.8
This product was developed by uniQure prior to being licensed to CSL Behring. However, there are many treatment goals that patients and their caregivers have that fall short of a cure, not only improvements but, for progressive conditions, a slowing or halting of worsening.
Simple ones, but still… This presented the student with a tantalizing future: the ability to fully model how a cell reacted to genetic perturbations. At best, the corporations with the best models released weak versions to the public under non-commercial licenses. Of particular interest was how genetic therapies were delivered.
“As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About Selva Therapeutics.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. About Molnupiravir.
Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.
AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. Preliminary analyses show similar adverse events in the placebo and treatment arms.
BY AMANDA CONTI | MAR 6, 2024 8:46 PM CST AgencyIQ’s quick primer on the influenza virus and how annual vaccine strains are selected Influenza viruses have caused untold illness and death through human history. A key part of the influenza virus’ ability to infect humans is hemagglutinin (HA), a glycoprotein found on the surface of the virus.
The UK government’s COVID-19 Vaccine Taskforce and a contract research company called Open Orphan announced a $13 million (£10 million) plan to test investigational COVID-19 vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes COVID-19. They will require regulatory and ethical approval.
Full results from PROVENT will be submitted for publication in a peer-reviewed medical journal and presented at a forthcoming medical meeting. AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. About PROVENT.
Vocabria is intended for adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. Elsewhere around the world: Avacta Group – U.K.-based
While traditional artificial intelligence/machine learning (AI/ML) offers some benefits, generative AI, particularly when integrated with clinical genomics, presents a transformative opportunity. Examples of large-scale applications and future perspectives are presented.
Our preclinical work at Gritstone developing our powerful prime-boost vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are very similar to HIV-1. This press release features multimedia. View the full release here: [link].
Ongoing research for baricitinib, an oral JAK inhibitor discovered by Incyte and licensed to Lilly, in adult and pediatric AD, alopecia areata (AA), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), COVID-19 and for its approved indication for rheumatoid arthritis (RA) continues.
Verrica Pharmaceuticals presented positive data from post-hoc pooled analyses of the pivotal Phase III CAMP trial of VP-102 in molluscum contagiosum. Transgene and BioInvent received approval from France’s national regulatory agency to begin a Phase I/IIa trial of Vaccinia virus BT-001 in solid tumors.
Detailed results from the BRAVE program will be presented at an upcoming medical conference and published in a peer-reviewed journal later this year. ” Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. Viral Reactivation – Viral reactivation, including cases of herpes virus reactivation (e.g.,
iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.
Full results from Paraphernalia will be submitted for publication in a peer- reviewed medical journal and presented at a forthcoming medical meeting. AZD7442 AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.
30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct. patients with a history of diverticulitis).
Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. This paper presents a massive CRISPR screen, in Arabidopsis, that identifies many genes with previously "hidden functions." Only about 15% of antibodies actually neutralize the new variants. Ricciardi M.J. Nature Plants.
1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. Due to the rapidly evolving and geographically diverse nature of the SARS-CoV-2 virus, continued scientific innovation remains critical to develop additional treatments. In the U.S.,
billion related to certain license and collaboration agreements, and certain other items.
Merck presented long-term findings from the EORTC1325/KEYNOTE-054 trial evaluating KEYTRUDA as adjuvant therapy in resected, high-risk stage III melanoma at the ESMO Virtual Congress 2020.
Non-GAAP EPS of $1.74
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. The sBLA is supported by data from the Phase 1/2 ZUMA-3 trial, which are also being submitted for presentation at an upcoming scientific congress.
The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. The research encompasses two projects. The study led by Dr. Ilya Trakht, Ph.D., About TNX-1800. 1 Noyce RS, et al. 2018) PLoS One. 13(1):e0188453.
A live webcast of this presentation will be available for registered participants at: [link]. This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. Riley Securities Oncology Investor Conference being held virtually.
New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology.
We are in an excellent position to take advantage of the opportunities these dynamics present – for the benefit of the people who use our products and, through sustainable growth, for the benefit of our stockholders,” said Baumann.
Detailed results from ZUMA-7 will be submitted for presentation at a future medical congress, and Kite plans to initiate discussions with the U.S. human herpes virus-6 [HHV-6] encephalitis and JC virus progressive multifocal leukoencephalopathy [PML]) have been reported.
I’m very excited by the opportunities presented by BetterLife’s experienced clinical research team enabling Transcend’s novel therapeutics to reach human beings in need of help.”. The regulatory hurdles and barriers associated with administering psychedelics to human subjects are staggering.
“Last week, Regeneron achieved an important milestone in the fight against COVID-19 with prospective Phase 2/3 results showing REGN-COV2 significantly reduced virus levels and the need for further medical attention in non-hospitalized patients; we have shared these important data with regulatory authorities,” said Leonard S.
Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Type 2 inflammation in asthma–present in most, absent in many. Amgen (NASDAQ:AMGN) announced that the U.S. Available at: [link] [Last accessed: April 2021]. Nat Rev Immunol.
It is an optimized, non-chemically modified mRNA that codes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. Biophytis presented preliminary analysis of its SARS-OBS trial evaluating the mobility, strength and physical activity of up to 100 sarcopenic patients. FLT180a is an AAV gene therapy.
The webcast and the presentation will be available within the Investors & Media section of HOOKIPA’s website at [link]. 3 The majority of CMV infections are not serious, and the virus can lay dormant in the body for years. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system.
Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.
billion declined, mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene. These are designed to target multiple different sites on the SARS-CoV-2 virus simultaneously for enhanced antiviral effects and potential use as both prophylactics and treatments. Free cash flow¹ of USD 1.6 Iptacopan (LNP023).
These windows depend on whether the new drug application (NDA) or biologics license application (BLA) is a new molecular entity, and if the application has received standard review (10 months, plus 2 months of administrative time) or priority review (6 months, plus 2 months of administrative time).
“The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. Here are just a few: About 30,000 people know how to synthesize an influenza virus, at a cost of about $5,000. ” The tool was crafted with a virus, called GIL16.
“The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. Here are just a few: About 30,000 people know how to synthesize an influenza virus, at a cost of about $5,000. ” The tool was crafted with a virus, called GIL16.
Results from the NAVIGATOR trial will be presented at an upcoming medical meeting. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Type 2 inflammation in asthma–present in most, absent in many. J Allergy Clin Immunol. 2014; 133: 388–94. 15 Fahy JV.
Prescription drug advertisements presented through media such as TV and radio must disclose the product’s major side effects and contraindications in what is sometimes called the major statement. This rule also establishes standards for determining whether the major statement in these advertisements is presented in the manner required.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content